financetom
Business
financetom
/
Business
/
Stellantis falls 7% in Paris after CEO Tavares resigns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis falls 7% in Paris after CEO Tavares resigns
Dec 2, 2024 12:13 AM

(Reuters) -Paris-listed shares in Stellantis ( STLA ) slumped by over 7% on Monday after chief executive Carlos Tavares resigned abruptly on Sunday.

Stellantis ( STLA ) said it would seek to find a replacement CEO in the first half of 2025 and would establish a new interim executive committee helmed by Chairman John Elkann.

Previously regarded as one of the most respected executives in the auto industry, Tavares' approach came under scrutiny after slumping sales in North American led the automaker in September to issue a profit warning on its 2024 results.

"This sets an unprecedented challenge for investors looking to invest in a firm with such volatility in the management team," JPMorgan said in a note referring to earlier resignation of Stellantis' ( STLA ) finance chief.

" ... with such a turnaround in the top management team, question marks may be raised as the market will in our view price in no major earnings improvement in FY25," they added.

"The difficulties of Stellantis ( STLA ) continue to cast doubts about the global brand conglomerate business model... as well as CEO longevity in an industry as structurally and cyclically challenged as Autos," Jefferies analysts said

Milan-listed shares, down more than 40% year-to-date, were halted in early trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Omeros prices transplant complication drug at $36,000 per dose
Omeros prices transplant complication drug at $36,000 per dose
Mar 10, 2026
By Puyaan Singh Jan 7 (Reuters) - Omeros ( OMER ) will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older ‌at $36,000 per single-dose vial, CEO Gregory Demopulos said ​on a call with analysts on Wednesday. Shares of ‍the company were up 6.6% ⁠in ⁠extended trade. The drug, sold under...
Musk lawsuit over OpenAI for-profit conversion can head to trial, US judge says
Musk lawsuit over OpenAI for-profit conversion can head to trial, US judge says
Mar 10, 2026
* Musk claims OpenAI violated its founding mission in restructuring to a for-profit entity * OpenAI denies claims, calls Musk's lawsuit baseless * Musk was a co-founder of OpenAI, now runs a rival AI company By Mike Scarcella WASHINGTON, Jan 7 (Reuters) - Billionaire entrepreneur Elon Musk persuaded a judge on Wednesday to allow a jury trial on his allegations...
OpenAI reserves $50 billion for stock grant pool, The Information reports
OpenAI reserves $50 billion for stock grant pool, The Information reports
Mar 10, 2026
Jan 7 (Reuters) - OpenAI set aside an ‌employee stock grant ​pool equivalent ‍to 10% ⁠of ⁠the company ‌last ​fall, which was valued ⁠at $500 ‍billion ​in October, The Information reported ‍on Wednesday, citing two people with ​knowledge ‍of the plans. Reuters ​could not immediately verify the report. ...
Trump calls for $1.5 trillion military budget in 2027
Trump calls for $1.5 trillion military budget in 2027
Mar 10, 2026
Jan 7 (Reuters) - President Donald Trump said on Wednesday the 2027 U.S. ‌military budget should be $1.5 trillion, significantly higher than the $901 billion ​approved by Congress for 2026, sending up defense ‍stocks. Any such increase in the ⁠military budget ⁠would require congressional authorization, but Trump's Republicans, who hold slim majorities ‌in both the Senate ​and House of Representatives,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved